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     BSTRACT
A thirteen-year-old, male, castrated, non-azotemic European Shorthair was presented for 
treatment of hyperthyroidism. Thyroid scintigraphy using Tc99m showed bilaterally enlarged 
thyroid glands with an increased thyroid to salivary (T/S) ratio. The cat was treated with an 
intravenous injection of 4.84 mCi (179MBa) 131I. One year later, the cat showed clinical deterio- 
ration, including lethargy, weight loss and a louder heart murmur; iatrogenic hypothyroidism 
was diagnosed. Concurrently, renal parameters were elevated compared to the pre-treatment 
values. Supplementation with levothyroxine was started. Four months later, the cat was euthy-
roid and improved creatinine values were noted. In this case report, the diagnosis and manage-
ment of iatrogenic hypothyroidism in cats and the interplay with renal function are described. 
An algorithm with recommendations regarding diagnosis, monitoring and treatment of these 
cats is presented.
SAMENVATTING
Een mannelijke, gecastreerde, niet-azotemische Europese korthaar van dertien jaar werd aange-
boden voor de behandeling van hyperthyroïdie. Schildklierscintigrafie met Tc99m onthulde bilateraal 
vergrote schildklieren met een toegenomen “thyroid to salivary (T/S) ratio”. De kat werd behandeld 
met 4,84mCi (179Mba) 131I. Een jaar later vertoonde de kat klinische achteruitgang, zoals lethargie, 
gewichtsverlies en een luidere hartruis; iatrogene hypothyroïdie werd gediagnosticeerd. Tegelijker-
tijd waren de nierwaarden gestegen ten opzichte van voor de behandeling. Een levothyroxinetherapie 
werd opgestart. Vier maanden later was de kat opnieuw euthyroïde en was de serum-creatininewaarde 
opnieuw gedaald. In deze casuïstiek worden de diagnostiek en het management beschreven van katten 
met iatrogene hypothyroïdie en het effect van iatrogene hypothyroïdie op de nierfunctie wordt nader 
toegelicht. Bijkomend wordt een algoritme opgesteld met aanbevelingen voor diagnostiek, monitoring 
en behandeling van hyperthyroïde katten die behandeld worden met radioactief jodium.
A
Case series  
INTRODUCTION
Hyperthyroidism is the most common endocrine 
disorder in elderly cats (Peterson and Ward, 2007). 
This disease can be treated pharmacologically, surgi-
cally, dietary or with radioiodine therapy (Daminet et 
al., 2014) (Table 1). 
Treatment with 131I is considered the gold standard 
in many cats as it is curative and safe. The adminis-
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tered radioiodine is taken up by the thyroid glands and 
the emitted β radiation destroys the nearby abnormal 
thyroid tissue. The remaining thyroid tissue is mostly 
atrophied, hence will be spared of most of the radia-
tion (Daminet et al., 2014; Daminet and Hill, 2017). 
131I treatment has a 90-95% success rate (Volckaert et 
al., 2016). The major disadvantages of 131I therapy are 
the need for a licenced, specialized center, the use of 
radioactive products, the need for hospitalization and 
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the possible development of iatrogenic hypothyroid-
ism (Table 1). 
Iatrogenic hypothyroidism has been reported in 
3-79% of all 131I-treated cats, although in most stud-
ies, a prevalence of iatrogenic hypothyroidism of ap-
proximately 10% has been shown (Meric and Rubin, 
1990; Boag et al., 2007; Lucy et al., 2017; Peterson et 
al., 2017). 
Cats with iatrogenic hypothyroidism rarely show 
obvious clinical signs. Lethargy, weight gain and an-
orexia are the most commonly noted. However, these 
clinical signs are difficult to recognize by the owner 
since resolution of hyperthyroidism should lead to 
improvement of the typical clinical signs of hyper-
thyroidism, including hyperactivity, polyphagia and 
weight loss. The combination of these vague clinical 
signs and the possible influence of concurrent illness 
on total thyroxine (TT4) concentrations (euthyroid 
sick syndrome) makes diagnosing iatrogenic hypo-
thyroidism after 131I treatment challenging (Peterson, 
2016). 
Once iatrogenic hypothyroidism has been diag-
nosed, the veterinarian can decide to either start treat-
ing the cat with thyroid hormone supplementation or 
continue monitoring. This decision can be difficult to 
make and depends on a combination of the presence 
or absence of clinical signs, the time of diagnosis and 
the renal values of the cat (Williams et al., 2014).
Once treatment with levothyroxine has been ini-
tiated, frequent re-evaluations should take place to 
evaluate the clinical response and to measure post-
treatment TT4 for therapeutic monitoring. This is 
important to avoid under- or overdosing of levothy-
roxine, with persistent hypothyroidism or iatrogenic 
hyperthyroidism as a consequence. Therapeutic mon-
itoring of total T4 concentrations should take place in 
every cat treated with levothyroxine, because many 
factors, including gastrointestinal disease and concur-
rent administrations of other medications, influence 
the absorption of levothyroxine (Daminet, 2016).
In this case report, the recommended protocols 
of diagnosing, treating and re-evaluating iatrogenic 
hypothyroid cats after radioiodine treatment are de-
scribed.
CASE DESCRIPTION
A thirteen-year-old, male, castrated European Short- 
hair was presented at the referring veterinarian with 
chronic weight loss, polyphagia and being quieter. 
The diagnosis of hyperthyroidism was confirmed 
based on increased serum TT4 concentration. Treat-
ment with methimazole was instituted, and the cat 
was referred to the Small Animal Clinic of the Faculty 
of Veterinary Medicine, Ghent University, for further 
work-up and possibly radioiodine treatment. Blood 
examination (including free T4 (fT4), TT4, hemato-
logy and biochemistry), urinalysis, thoracic X-rays, 
echocardiography and an abdominal ultrasound were 
Table 1. Summary of considerations regarding treatment options for feline hyperthyroidism. (Adapted from Daminet, 
2019).
 Anti-thyroid Restricted Thyroidectomy 131I
 drugs iodine diet 
 
Initial cost + + +++ +++
Long-term cost ++ ++ + +
Pre-requisites None Strict administration Skilled Licenced facility
  of this diet needs surgeon
  to be possible   
Ease of use for the owner Easy to Easy Easy after Radioprotective
 moderate   hospitalization measures needed,
    afterwards easy
Need for anesthesia No No Always Sometimes 
Time to euthyroid 2-4 weeks 6-8 weeks  1-2 days Days to weeks
Hospitalization No No 1-3 days 3 days to 4 weeks
Potential limitation Mild side-effects Low palatability Recurrence after Iatrogenic
 common in some cats unilateral/ hypothyroidism
   incomplete or persistent
   thyroidectomy hyperthyroidism
    possible
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performed as part of an extensive work-up for a pro-
spective study. 
Initial physical examination revealed typical clini-
cal features of hyperthyroidism including muscle at-
rophy, palpation of a goitre and a systolic heart mur-
mur (Table 2). 
Initial blood examination, including biochemistry, 
hematology and thyroid profile, confirmed the diag-
nosis of hyperthyroidism with severely increased TT4 
and fT4 values and a low normal TSH concentration 
(Table 3). 
Urinalysis prior to the 131I treatment revealed con-
centrated urine with mild proteinuria (Table 4). Chest 
X-rays revealed mild cardiomegaly. Echocardiogra-
phy visualized mild hypertrophy of the left ventricle 
with borderline left atrium dilation and dynamic right 
ventricular outflow tract obstruction (DRVOTO). Ab-
dominal ultrasound did not reveal any significant ab-
normalities.  
Thyroid scintigraphy with Tc-99m showed bilater-
al enlarged thyroid glands with an increased tracer up-
take (Figure 1). The left thyroid gland was displaced 
caudally. The thyroid-to-salivary (T/S) ratio was in-
creased in both left (10/1) and right (3.9/1) thyroid 
glands. 
The results obtained from bloodwork and pertech-
netate scan in this cat were consistent with the con-
firmed hyperthyroidism. Treatment with an intrave-
nous injection of 4.84mCi (179MBq) 131I was institut-
ed. This dose was based on the T/S ratio obtained via 
scintigraphy, TT4 value and clinical signs (Volckaert 
et al., 2016). The cat was hospitalized for five days 
due to radioprotective precautions.
One month post-treatment control included uri-
nalysis, abdominal ultrasound and echocardiography. 
Significant clinical improvement was noticed (Table 
2). Bloodwork revealed TT4 and fT4 serum concen-
trations that had dropped below the reference interval 
and serum TSH concentration well within the upper 
range of the reference interval. The serum creatinine 
and urea concentrations were still within reference in-
terval, but had significantly increased compared to the 
pre-treatment serum concentrations  (Table 3). Urinaly- 
sis revealed decreased urine concentration compared 
to the baseline values (Table 4). 
The patient returned for a control visit one year 
after treatment. Blood and urine examinations, scinti-
graphy, abdominal ultrasound and echocardiography 
were performed. Significant clinical deterioration in-
cluding weight loss, mild muscle wastage and a loud-
er heart murmur was noticed and the cat had become 
significantly more quiet at home (Table 2). The patient 
was also hypertensive with a mean blood pressure of 
205mmHg (measured with Doppler ultrasonography).
Control bloodwork showed low normal serum 
TT4 and decreased serum fT4 values, combined with 
a high serum TSH concentration (Table 3). Concur-
rent renal disease was also suspected based on an in-
crease in serum values of SDMA, urea and creatinine 
compared to pre-treatment and significant proteinuria 
(Tables 3 and 4). The rest of the performed blood-
work, including full hematology, biochemistry and 
electrolytes, was unremarkable. 
Both thyroid glands could no longer be clearly 
Figure 1. Pertechnetate scan in a hyperthyroid cat prior 
to 131I treatment.
Table 2. Findings on physical examination in a hyperthyroid cat prior to 131I, and at one and twelve months later (T0, 
T1 and T12, respectively).
 
 T0 T1 T12
Muscle condition score Moderate muscle atrophy No muscle atrophy Mild muscle atrophy
Weight (kg) 2.8 3.6 3.02
Thyroid gland palpation* 5/6 L - 0/6 R 4/6 L - 0/6 R 0/6 L – 0/6 R
Body condition score (BCS) 4/9 5/9 4/9
Heart murmur 3/6 1-2/6 3/6
*Thyroid gland scoring system: score 0 = non-palpable thyroid gland; score 1 =1-3 mm; score 2 = 3-5 mm; score 3 = 5-8 
mm; score 4 = 8-12mm; score 5 = 12-25mm and score 6 = ≥25 mm (Boretti et al., 2005; Paepe et al., 2008).
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delineated due to decreased radionuclide uptake on 
thyroid scintigraphy (Figure 2). The T/S ratio was es-
timated to be 0.78/1, but was hard to determine due 
to the limited visibility of the thyroid glands on scin-
tigraphy. 
Based on the low normal TT4, low fT4, increased 
TSH concentration and decreased radionuclide uptake 
on scintigraphy, this cat was diagnosed with iatroge-
nic hypothyroidism one year after 131I treatment. 
Echocardiography showed a mild, focal thicken-
ing of the septum with very mild dilation of the left 
atrium. These findings did not have any clinically 
relevance at that time point. Abdominal ultrasound 
didn’t show any significant abnormalities. 
Supplementation with levothyroxine (Leventa MSD 
animal health, United Kingdom; 0,075ml = 0.075mg 
twice daily) was prescribed.
Control bloodwork was performed four months 
after the initiation of thyroxine supplementation. The 
serum TT4 concentration was within normal limits 
and the urea and creatinine values were mildly de-
creased. The cat had improved clinically. However, 
the serum SDMA concentrations were further in-
creased (Table 3). 
DISCUSSION
Although radioiodine treatment is the preferred 
treatment option for hyperthyroidism, in some cats, it 
also involves disadvantages and complications. One 
of the main complications is the potential develop-
ment of iatrogenic hypothyroidism (Meric and Rubin, 
1990; Boag et al., 2007; Lucy et al., 2017; Peterson et 
al. 2017).
One of the predisposing factors for 131I therapy in-
duced iatrogenic hypothyroidism is the usage of (too) 
high doses of radioiodine. The standard dose for treat-
ing hyperthyroidism in cats with 131I used to be ap-
proximately 4-5 mCi, but recently, it has been shown 
that with a dose of 2mCi, most cats with mild-to- 
moderate hyperthyroidism without an increased fre-
quency of persistent hyperthyroidism three and six 
Figure 2. Pertechnetate scan in an iatrogenic hypo-
thyroid cat, twelve months after 131I treatment to treat 
hyperthyroidism.
Table 3. Findings on serum biochemistry in a hyperthyroid cat prior to 131I, and at one, twelve and sixteen months 
after treatment (T0, T1, T12 and T16, respectively). 
 Results Results Results Results Reference 
  T0  T1 T12 T16 interval
Total T4 >167.3 9 15.4 33.54 10-60 nmol/l
Free T4 (Immulite) 77.2 4.5 4.2  9.0-33.5 pmol/l
Free T4 (Equilibrium dialysis) 108.7 5 11.2  9.0-33.5 pmol/l
TSH 0.03 0.11 0.58  0.03-0.3 ng/ml *
Urea 6.2 11.7 12.4 10.16 5.7-13.5 nmol/l
Creatinine 48 103 123 106.1 <168 µmol/l
SDMA 9 9 17 20 0-14 µg/dl
Bilirubin 1.7 2,7 2.7  <6.8 µmol/l
ALT 277 150 129  <175 U/l
ALP 155 46 36  <73 U/l
GGT <1 1 1  <5 U/l
AST 131 60 48  <71 U/l
Total Calcium 2.3 2.5 2.3  2,2-2,9 mmol/L
Total Protein 59  78  59-87 g/l
Albumin 25  30  27-44 g/l
Globulin 34  48  29-54 g/l
SDMA = Symmetric dimethylarginine; ALT = Alanine aminotransferase; ALP = Alkaline phosphatase; GGT = gamma 
glutamyl transferase; AST = aspartate aminotransferase 
*Based on Lucy et al. (2017).
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months post therapy can be successfully treated (Lucy 
et al., 2017). Although the dosage currently used in the 
clinic at the Faculty of Veterinary Medicine (Ghent 
University) has been adapted to 2mCi, the cat in the 
present case, treated in November 2016, still received 
4.84 mCi 131I, which is nowadays considered to be a 
high dose. Another predisposing factor for iatrogenic 
hypothyroidism is the presence of bilateral 131I uptake 
on thyroid scintigraphy. These cats, including the cat 
in the present case report, are twice as likely to deve-
lop iatrogenic hypothyroidism compared to cats with 
only unilateral thyroid pertechnetate uptake (Nykamp 
et al., 2005). 
Follow-up of the clinical status and bloodwork af-
ter radioiodine treatment is of great importance to be 
able to make an early diagnosis of iatrogenic hypothy-
roidism. However, a complete work-up for iatrogenic 
hypothyroidism in non-azotemic cats is not recom-
mended until three to six months post-treatment, be-
cause cats treated with 131I can become transient hypo-
thyroid. These cats regain a normal thyroid function 
within three to six months after treatment (Peterson 
et al., 2017). Considering that the cat in the present 
case was hypothyroid one year post-treatment, chanc-
es were very low that he would become spontane-
ously euthyroid again. Azotemic cats that have been 
treated with 131I, should be monitored more closely, 
because treatment for hyperthyroidism, development 
of iatrogenic hypothyroidism and potential concurrent 
CKD all decrease the glomerular filtration rate (GFR). 
Iatrogenic hypothyroidism should be diagnosed and 
treated as early as possible, since it improves renal 
function and provides a longer median survival time 
in these cats (Williams et al., 2014; Peterson et al., 
2017).
The diagnosis of iatrogenic hypothyroidism is cur-
rently based on the measurement of serum TT4 and 
TSH concentrations. Elderly, euthyroid cats often 
have low TT4 concentrations due to concurrent non-
thyroid illnesses (Peterson, 2016). Free T4 concen-
trations are less influenced by non-thyroidal illness 
and are therefore considered to be more sensitive for 
diagnosing iatrogenic hypothyroidism. However, the 
assays available for the measurement of fT4 concen-
trations have a variable performance and accuracy. 
Determining fT4 after equilibrium dialysis (FT4ED) 
is considered the gold standard. However, FT4ED 
is an expensive and time-consuming test that is not 
widely available. In a recent study by Stammeleer et 
al. (2018), the measurement of fT4 via a chemilumi-
niscent enzyme immunoassay (FT4CEIA) has shown 
correlating, but consistently lower results compared 
to FT4ED. However, approximately 75% of iatrogen-
ic hypothyroid cats have fT4 values within reference 
interval (Peterson et al., 2017). Therefore, it is recom-
mended to interpret serum TT4 results in combina-
tion with serum TSH concentrations (Peterson et al., 
2017). 
Currently, there is no feline TSH assay available. 
The immulite canine TSH assay (Diagnostic Products 
Corporation, DPC), a chemiluminescent immuno- 
metric assay, is being used to determine TSH concen-
trations in cats because of the cross-reaction of this 
assay with feline TSH. Multiple studies have been 
performed to determine a reference interval (RI) 
for TSH in healthy, elderly cats. The suggested up-
per reference limit of feline TSH determined by the 
cTSH assay varies between 0.15 ng/ml and 0.3 ng/ml 
(Wakeling, 2010; Williams et al., 2010; Lucy et al., 
2017). However, the choice between these two cut-
off values will have a major influence on the amount 
of iatrogenic hypothyroid cats that will be diagnosed 
after 131I treatment. This emphasizes the need of fur-
ther studies to determine the most appropriate cut-off 
value for this assay in order to be able to diagnose 
iatrogenic hypothyroidism in cats. In addition, a re-
cent study from Stammeleer et al. (2019) showed that 
approximately 27% of cats with high cTSH concen-
trations are euthyroid based on scintigraphy. In that 
study, TT4 concentrations were within the reference 
interval in all of these euthyroid cats with increased 
cTSH concentrations, which shows us the need to in-
terpret TT4 and TSH concentrations together and with 
caution. 
A TSH stimulation test using recombinant human 
TSH (rhTSH) can also be used to assess the thyroid 
function. Serum samples should be collected before 
and 6 hours after IV administration of the exogenous 
rhTSH. A study by Van Hoek et al. (2010) showed that 
iatrogenic hypothyroid cats do not show a significant 
increase in TT4 after the administration of rhTSH, in 
contrast to healthy cats or cats with non-thyroid ill-
ness. One of the main disadvantages of this test is the 
high cost for a vial of rhTSH. However, once opened, 
these vials can be stored for four to eight weeks with-
out any loss of biological activity, making it possible 
to perform multiple TSH stimulation tests with one 
vial (De Roover et al., 2006). 
Table 4. Findings on urinalysis in a hyperthyroid cat prior to 131I, and at one and twelve months after treatment (T0, 
T1 and T12, respectively).
  Result T0 Result T1 Result T12 Reference interval
 Specific gravity >1.050 1.015 1.020 
 UPC 0.6 0.2 2.9 0-0.4
UPC= urine protein:creatinine ratio
320 Vlaams Diergeneeskundig Tijdschrift, 2020, 89
Thyroid scintigraphy is considered the best imag-
ing modality to diagnose iatrogenic hypothyroidism 
in cats that had received radioiodine treatment. Cats 
with true iatrogenic hypothyroidism show decreased 
or absent radionuclide uptake on scintigraphy, where-
as cats with low T4 concentrations due to non-thyroi-
dal illness have a normal radionuclide uptake (Peter-
son, 2013). However, cats that become hypothyroid 
after methimazole treatment should not be diagnosed 
with scintigraphy since methimazole can potentially 
increase the radionuclide uptake, causing a falsely 
increased T/S ratio (Peterson and Broome, 2015). 
Unfortunately, thyroid scintigraphy is currently not 
routinely available for most veterinarians (Peterson, 
2013).  
Whether or not iatrogenic hypothyroidism should 
be treated immediately or monitored depends on 
the renal function of the cat. When bloodwork does 
not reveal azotemia, the iatrogenic hypothyroidism 
should not be treated within the first six months after 
131I treatment. However, if the cat is azotemic, treat-
ment with thyroid hormone supplementation has been 
shown to improve renal function and increase the 
median survival time in these cases (Williams et al., 
2014; Vaske et al., 2015; Peterson et al, 2017). An al-
gorithm with recommendations regarding diagnosis, 
monitoring and treatment of hyperthyroid cats treated 
with 131I is presented in Figure 3. 
Unfortunately, currently, there is no reliable test 
available that predicts post-treatment azotemia in 
hyperthyroid cats. Serum creatinine (sCr) concentra-
tions are influenced by body muscle mass, which is 
usually decreased in hyperthyroid cats. Increased glo-
merular filtration rate (GFR) in hyperthyroid cats also 
leads to decreased sCr concentrations, which makes 
it a less optimal indicator for azotemia in these cats. 
Direct measurement of GFR is not frequently used 
in clinical settings because the process is time-de-
manding and potentially stressful for the cats. Serum 
symmetric dimethylarginine (SDMA), a byproduct of 
cellular protein metabolism, is not affected by these 
extrarenal factors and is therefore suspected to be a 
better biomarker for the detection of CKD. However, 
SDMA has a poor sensitivity (33%) to diagnose early 
kidney disease in hyperthyroid cats (Peterson et al., 
2018). In addition, Burresova et al. (2019) showed 
that cats treated with 131I show a poor correlation be-
tween SDMA and GFR. 
One month post treatment, the cat in the present 
case already showed decreased TT4 concentrations 
with normal TSH concentrations. Treatment with L-
thyroxine was not instituted at this point in time be-
cause 1. only a short period had elapsed after treat-
ment, which could reflect transient hypothyroidism; 
2. the kidney values remained within the reference 
interval; 3. no obvious clinical signs of hypothyroi-
Figure 3. Algorithm with recommendations regarding the diagnosis, monitoring and treatment for cats treated with 
131I (Adapted from Daminet S., 2016).
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dism were observed and 4. TSH was not significantly 
increased. 
One year post treatment, the patient was orally ad-
ministered levothyroxine because of low serum fT4 
concentrations, high serum TSH concentration, de-
creased thyroid visibility on thyroid scintigraphy, in-
creasing kidney values (still within reference interval) 
and hypertension. At that time point, the cat became 
lethargic and had mild weight loss (but still a normal 
body condition score). Lethargy is a common clinical 
sign in cats with iatrogenic hypothyroidism. Weight 
loss, however, is unfrequently noticed in hypothyroid 
cats (Peterson, 2013). Further diagnostic tests were 
performed in the cat of the present case, including an 
extensive blood examination, urinalysis, abdominal 
ultrasound and echocardiography, which didn’t reveal 
other abnormalities besides the mild increase in renal 
values, proteinuria and hypertension. For this reason, 
it was recommended to closely follow-up these renal 
parameters after the initiation of treatment with oral 
levothyroxine. In addition, the cat showed significant 
clinical improvement once this treatment was started. 
In the present case, the thyroxine and TSH concen-
trations had not been monitored for six months after 
treatment,  due to a loss of follow-up at that time; other- 
wise, treatment in this cat might have been initiated 
sooner.
After starting levothyroxine supplementation, im- 
provement of the mental status and activity level 
should be noticed within a couple of days. After a 
couple of weeks, weight loss might be noticed and the 
hair coat should improve within the first few months. 
Blood examination should be performed four to eight 
weeks after the start of the treatment and should in-
clude serum urea, creatinine, T4 (TT4 or fT4) and 
TSH concentrations. Post-treatment blood samples 
should be collected approximately four hours after 
the levothyroxine supplementation in order to be able 
to measure T4 peak serum concentrations. Ideally, T4 
concentrations rise and TSH concentrations drop into 
the reference interval. If these values are not reached, 
dose adjustment is advised (Daminet, 2016). In the 
present case, the TT4 concentration increased into the 
reference interval, renal variables decreased and the 
cat was clinically stable, hence no dose adjustment 
was instituted. The serum SDMA concentration in the 
present case was higher than one year after the 131I 
treatment. There are currently no studies available in 
which the correlation of sSDMA and GFR has been 
examined in iatrogenic hypothyroid cats treated with 
levothyroxine, which makes the interpretation of this 
result challenging. 
It is important to note that also medical treatment 
with methimazole can cause iatrogenic hypothyroid-
ism in cats. Between 20 - 40% of cats treated with me-
thimazole become iatrogenic hypothyroid (Aldridge 
et al., 2015). Many of these cats have TSH concentra-
tions within the reference interval during the first three 
months of treatment, but iatrogenic hypothyroidism 
often occurs at a later stage of treatment (Aldridge et 
al., 2015). Just as in cats treated with 131I, TT4 or fT4 
values should always be interpreted in combination 
with TSH concentrations. This emphasizes the impor-
tance of closely monitoring these cats, including regu-
lar bloodwork to check T4 and TSH concentrations 
in cats treated with methimazole. When low/normal 
low T4 concentrations and high TSH concentrations 
are found, the methimazole dose should be lowered, 
even in the absence of clear clinical signs (Aldridge 
et al., 2015). 
CONCLUSION
Diagnosing, monitoring and treating iatrogenic 
hypothyroidism in cats can be challenging. Making 
the decision to start thyroid hormone supplementation 
can be difficult as iatrogenic hypothyroidism can be 
transient. Currently, thyroid hormone supplementa-
tion is always recommended in azotemic cats as iatro-
genic hypothyroidism could negatively influence sur-
vival rates in these cats (Figure 3).
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